{"id":"cetugex","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CetuGEX works by binding to the CD137 receptor, also known as 4-1BB, which is expressed on the surface of activated T cells. This binding activates the receptor, leading to an increase in T cell proliferation and activation, and ultimately, an enhanced immune response against cancer cells.","oneSentence":"CetuGEX targets the CD137 receptor to stimulate an immune response against cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:56.194Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT02052960","phase":"PHASE2","title":"CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"Glycotope GmbH","startDate":"2014-02","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":240},{"nctId":"NCT01222637","phase":"PHASE1","title":"CetuGEX™: Phase 1 Study in Cancer Patients","status":"COMPLETED","sponsor":"Glycotope GmbH","startDate":"2010-08","conditions":"Solid Tumors","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["tomuzotuximab","Tomuzotuximab"],"phase":"phase_2","status":"active","brandName":"CetuGEX™","genericName":"CetuGEX™","companyName":"Glycotope GmbH","companyId":"glycotope-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CetuGEX targets the CD137 receptor to stimulate an immune response against cancer cells. Used for Metastatic melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}